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ABSTRACT % 
Over the last few years, the use of valproate in psychiatry has increased considerably. With 
the advent of oral loading dose strategy, its role in rapid treatment of acute mania has been 
demonstrated. The intravenous formulation of valproate, while retaining the rapidity of action of oral 
loading, also avoids some of the adverse effects of the oral preparation. Moreover, reports are 
pouring in that intravenous valproate loading may be more efficacious than oral valproate loading in 
the treatment of acute mania. We report two patients whose manic symptoms showed a dramatic 
response to intravenous valproate without adverse effects. The pharmacology of intravenous valproate 
and its clinical relevance to psychiatry are discussed. 
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Studies in the last decade have 
demonstrated that oral loading doses of sodium 
valproate is effective in controlling symptoms of 
acute mania (Keck et al., 1993; Martinez et al., 
1998). Although intravenous formulation of 
valproate is in use in Europe for over a decade, 
much of its initial literature was limited to 
treatment of epileptic patients, especially those 
with status epileptics (Hovinga et al., 1999). Its 
use in neuropsychiatry is more recent with reports 
of its effectiveness in acute mania (Erfurth & 
Grunze, 1998; Norton & Quarles, 2000; Norton, 
2000), agitation of autism (Hiltyetal., 1998)and 
bipolar disorder with Alzheimer's dementia 
(Herbert & Nelson, 2000). It has not been effective 
in bipolar patients with pure depression (Grunze 
et al., 1999). Further, intravenous valproate 
appears suitable for those manic patients who 
refuse oral medications or cannot tolerate oral 
medicines due to adverse effects, especially 
gastrointestinal symptoms after gastric bypass 
surgery (Kaltsounis & De Leon, 2000). In line with 
the growing interest, we present two cases in 
which acute manic symptoms responded well to 
intravenous valproate and discuss the 
pharmacological and clinical perspectives of this 
new modality of treatment of acute mania. 
CASE REPORT 
Case 1: D.K., a 36-year-old male, diagnosed with 
bipolar disorder was admitted for third episode of 
mania with psychotic symptoms and comorbid 
cannabis harmful use as per the ICD-10 diagnostic 
criteria (World Health Organisation, 1992). The 
present episode was of 10 days duration and it 
was consequent to poor compliance with lithium. 
On admission, the patient was very hyperactive 
and aggressive and had overtalkativeness, flight 
of ideas, elated affect, increased libido, delusions 
of grandeur and persecution and poor insight. He 
refused oral medications and was considered for 
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valproate infusion. After baseline liver function tests 
(LFT) and platelet counts, he was started on 550 
mg of i.v. valproate twice/day. The dose was 
calculated at 20 mg/kg body weight. The rate of 
infusion was not to exceed 20mg/min and the dose 
of valproate (550 mg) was mixed with 100ml of 
5% dextrose to be infused over one hour (Facts 
& Comparison, 1998; Norton & Quarles, 2000). A 
total of six doses were administered over three 
days after which the patient was switched to 
equivalent doses of oral valproate. His baseline 
score on a scale for manic symptoms (Cassidy 
etal., 1998) before the start of treatment witlw. v. 
valproate (day 0) was 47, which dropped to 34 on 
day 3 and to 9 on day 6. The domains showing 
maximal improvement within three days of 
starting the treatment with i.v. valproate included 
increased motor activity, paranoia, aggression and 
irritability. This improvement continued when the 
patient was switched to oral valproate so that by 
day 9, his score on the mania rating scale was 
zero. The patient was not prescribed any 
concomitant neuroleptics and parenteral 
lorazepam was prescibed on prn basis, the total 
dose not exceeding 4 mg/day. Adverse effects 
due to valproate were rated using a checklist and 
the patient did not report any of these, including 
injection site reactions. His LFT and platelet 
counts a week after the start of valporate were 
within normal limits. 
Case2: D.S., a 38-year-old male was admitted 
with a diagnosis of schizoaffective disorder, 
manic type (as per ICD-10) of 17 years duration. 
The patient was initially treated with oral 
neuroleptics but due to poor compliance was 
commenced on depot neuroleptics. However, he 
continued to deteriorate while continuing this 
medication and his present admission was 
prompted by an acute exacerbation of symptoms. 
On admission, he had mannerisms, over 
talkativeness, irritable and elated affect, racing 
thoughts, loosening of association, delusions of 
grandeur, persecution and reference and poor 
insight. It was decided to start the patient on 
clozapine but for the stabilization of acute phase, 
i.v.valproate was chosen which was to be 
continued in oral form along with clozapine. After 
baseline investigations as for case 1, the patient 
was treated with 750 mg twice/day of i.v.valproate, 
the dose being infused with 150ml of normal saline 
at a similar rate as in the previous case. Patient 
received six doses of i.v. valproate and it was 
converted to equivalent doses of oral valproate. 
The patient's baseline score (day 0) on the mania 
rating scale was 51 while that on Brief Psychiatric 
Rating Scale was 63. On day 3, the respective 
scores were 29 and 40 and on day 6 these were 
21 and 33. The areas showing maximal 
improvement within three days of valproate 
infusion were increased motor activity, decreased 
sleep, irritability and aggression on the mania 
rating scale and anxiety, grandiosity, tension, 
excitement, mannerism and uncooperativeness 
on the BPRS. He did not experience any side 
effects while being on i.v. valproate and other 
laboratory tests were also normal. 
DISCUSSION 
This report demonstrates that intravenous 
valproate is effective in controlling manic 
symptoms in bipolar disorder and schizoaffective 
disorder. There was a rapid response in either 
case, with the second patient showing more than 
40% improvement in manic symptoms within three 
days of treatment with i.v. valproate with the 
improvement continuing with oral valproate. This 
in fact is comparable or even faster than the 
response obtained with oral valproate loading 
(Keck et al., 1993). Moreover, to our knowledge 
this is the first report to show effective treatment 
of manic symptoms in a case of schizoaffective 
disorder, manic type, with i.v. valproate, which is 
in contrast to an earlier report that had failed to 
show improvement in schizoaffective disorder 
(Grunze et al., 1999). A notable observation was 
that both the patients had responded to valproate 
alone without concurrent neuroleptics though both 
had psychotic symptoms at presentation. 
Although regarded as safer than other 
anticonvulsants, i.v. valproate is not entirely free 
from side effects. The more common of these 
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included nausea, vomiting, headache, 
somnolence, dizziness, injection site reactions 
and taste perversion (Devinsky et al., 1995). 
However, neither patient showed any adverse 
reactions to i.v. valproate. 
Pharmacokinetic profiles of intravenous 
loading, a quick saturation of plasma binding of 
proteins and a rapid achievement of peak 
concentrations of valproate, which is about 22% 
higher than those obtained with the equivalent oral 
dosage, have been the proposed reasons for its 
rapid onset of action over oral valproate loading 
(Wangemann et al., 1997; Grunze et al., 1999). 
A rapid initial increase in peak concentration 
might be needed to induce certain intracellular 
changes before compensatory down-regulation of 
synaptic receptors and transmembranous 
transducing systems can occur (Erfurth & Grunze, 
1998). Further, intravenous valproate may cause 
a rapid saturation of plasma-binding proteins, 
which could increase the initial serum 
concentration of the active unbound drug and thus 
result in rapid attainment of high cerebral valproate 
levels (Grunze et al., 1999). In line with this, a 
study cites greater unbound fraction of the drug 
than expected in patients of status epilepticus 
treated with i.v. valproate (Hovinga et al., 1999). 
In sum, i.v. valproate is a promising and 
safe drug, which expands the spectrum of 
treatment options available for acute manic 
symptoms. However, before its widespread use 
in psychiatry, more studies are required to 
establish the optimal initial dosage and 
administrating rate. In this direction, a controlled 
study with a larger sample size and concurrent 
monitoring of serum valproate levels would 
overcome some of the limitations of our endeavor. 
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